Envestnet Asset Management Inc. Grows Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Envestnet Asset Management Inc. lifted its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 7.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,161 shares of the biopharmaceutical company’s stock after purchasing an additional 1,733 shares during the period. Envestnet Asset Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $1,119,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of RARE. Signaturefd LLC lifted its holdings in Ultragenyx Pharmaceutical by 151.0% during the 3rd quarter. Signaturefd LLC now owns 600 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 361 shares during the last quarter. Lazard Asset Management LLC lifted its stake in Ultragenyx Pharmaceutical by 36.6% in the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 240 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Ultragenyx Pharmaceutical by 26.1% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,264 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 469 shares in the last quarter. Maryland State Retirement & Pension System acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at $217,000. Finally, Martingale Asset Management L P raised its holdings in Ultragenyx Pharmaceutical by 28.5% in the 3rd quarter. Martingale Asset Management L P now owns 5,406 shares of the biopharmaceutical company’s stock valued at $224,000 after acquiring an additional 1,200 shares during the last quarter. 93.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RARE. Credit Suisse Group restated an “outperform” rating and set a $96.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Friday, February 17th. Cantor Fitzgerald assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, April 26th. They issued an “overweight” rating and a $114.00 price objective for the company. Morgan Stanley reduced their price target on shares of Ultragenyx Pharmaceutical from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, February 3rd. 1-800-FLOWERS.COM reaffirmed a “maintains” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, May 8th. Finally, Citigroup reduced their price target on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 in a research report on Friday, March 17th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $90.25.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE opened at $49.98 on Thursday. Ultragenyx Pharmaceutical Inc. has a twelve month low of $33.36 and a twelve month high of $68.68. The stock has a market cap of $3.54 billion, a price-to-earnings ratio of -4.88 and a beta of 0.94. The firm’s 50 day moving average price is $42.56 and its two-hundred day moving average price is $42.27.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($2.33) EPS for the quarter, missing the consensus estimate of ($1.97) by ($0.36). Ultragenyx Pharmaceutical had a negative net margin of 187.31% and a negative return on equity of 149.75%. The company had revenue of $100.50 million for the quarter, compared to analysts’ expectations of $103.90 million. During the same quarter in the prior year, the firm earned ($2.19) earnings per share. The company’s revenue was up 25.8% on a year-over-year basis. On average, research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -8.4 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 4,378 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $45.00, for a total value of $197,010.00. Following the completion of the sale, the executive vice president now owns 51,982 shares of the company’s stock, valued at approximately $2,339,190. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 4,378 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $45.00, for a total transaction of $197,010.00. Following the completion of the transaction, the executive vice president now owns 51,982 shares of the company’s stock, valued at approximately $2,339,190. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Camille L. Bedrosian sold 3,881 shares of the business’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $45.25, for a total transaction of $175,615.25. Following the transaction, the executive vice president now directly owns 46,720 shares of the company’s stock, valued at approximately $2,114,080. The disclosure for this sale can be found here. In the last 90 days, insiders sold 11,299 shares of company stock valued at $518,716. Insiders own 6.70% of the company’s stock.

Ultragenyx Pharmaceutical Profile

(Get Rating)

Ultragenyx Pharmaceutical, Inc engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.